Suchergebnisse - "Rosaria Volpini"

1

Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases

von: Diego Dal Ben

2018, in: Frontiers in Pharmacology

Wird geladen...
2

P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications

von: Andrea Spinaci

2021, in: Frontiers in Pharmacology

Wird geladen...
3

Non-Nucleoside Agonists of the Adenosine Receptors: An Overview

von: Diego Dal Ben

2019, in: Pharmaceuticals

Wird geladen...
4

Combined Therapy of A

von: Gabriella Marucci

2021, in: Molecules

Wird geladen...
5

Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists

von: Daniela Catarzi

2019, in: Pharmaceuticals

Wird geladen...
6

A

von: Andrea Spinaci

2022, in: Pharmaceuticals

Wird geladen...
7

Multipotent Stromal Cells from Subcutaneous Adipose Tissue of Normal Weight and Obese Subjects: Modulation of Their Adipogenic Differentiation by Adenosine A

von: Mariachiara Zuccarini

2021, in: Cells

Wird geladen...
8

Dual Anta-Inhibitors Targeting Protein Kinase CK1δ and A

von: Beatrice Francucci

2023, in: Molecules

Wird geladen...
9

Adenosine Receptors as Neuroinflammation Modulators: Role of A

von: Aleix Martí Navia

2020, in: Cells

Wird geladen...
10

Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives with High Affinity for Both the Adenosine A

von: Flavia Varano

2021, in: Pharmaceuticals

Wird geladen...
11

4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives

von: Daniela Catarzi

2022, in: Pharmaceuticals

Wird geladen...
12

The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A

von: Luca Antonioli

2020, in: Cells

Wird geladen...
13

A

von: Andrea Spinaci

2022, in: Molecules

Wird geladen...
14

“Dual Anta-Inhibitors” of the A

von: Andrea Spinaci

2023, in: Pharmaceuticals

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!